Table 1 Baseline characteristics of the study population
|  | Spironolactone (n = 9) | Alternative drug regimen (n = 8) | p value |
|---|---|---|---|
Sociodemographic and clinical characteristics | |||
 Age (years) | 64.6 (9.6) | 61.0 (6.6) | 0.15 |
 Sex (male/female) | 3/6 | 5/3 | 0.34 |
 Smoking | 0 | 0 | – |
 Alcoholic index (g/l) | 0 | 0 | – |
 Body mass index (kg/m2) | 30.3 (5.4) | 30.5 (7.7) | 0.95 |
 Waist circumference (cm) | 104.8 (12.5) | 102.7 (10.2) | 0.74 |
 Office SBPa (mmHg) | 158 (17) | 158 (8) | 0.96 |
 Office DBPa (mmHg) | 86 (11) | 94 (8) | 0.08 |
 Office heart rate (beats/minute) | 75 (12) | 76 (1) 6 | 0.92 |
 Self-measured SBP (mmHg) | 140 (9) | 151 (15) | 0.06 |
 Self-measured DBP (mmHg) | 78 (8) | 91 (15) | 0.07 |
Biological parameters | |||
 Fasting glycaemia (g/l) | 182.89 (105.45) | 141.13 (56.36) | 0.33 |
 Glycatedhaemoglobin (%) | 8.45 (1.76) | 8.64 (2.43) | 0.88 |
 Blood urea nitrogen (g/l) | 0.48 (0.01) | 0.48 (0.04) | 0.96 |
 Serum creatinine (mg/l) | 15.63 (5.97) | 12.45 (3.41) | 0.20 |
 eGFR (ml/min/1.73 m2) | 55.25 (23.76) | 73.99 (27.96) | 0.15 |
 Serum potassium (mmol/l) | 4.02 (0.15) | 4.01 (0.10) | 0.88 |
 Serum sodium (mmol/l) | 140.5 (0.5) | 141.0(0.7) | 0.11 |
 Serum total cholesterol (g/l) | 1.71 (0.39) | 2.21 (1.00) | 0.43 |
 Serum HDL-C (g/l) | 0.58 (0.09) | 0.35 (0.10) | 0.06 |
 Serum LDL-C (g/l) | 0.88 (0.35) | 1.54 (1.20) | 0.43 |
 Serum triglyceride (g/l) | 1.32 (0.98) | 1.63 (1.43) | 0.90 |
 Proteinuria (number of +) | 1.11 (1.6) | 1 (1.06) | 0.84 |
Complications | |||
 Chronic kidney disease | 9 (100) | 8 (100) |  |